Application of puerarin or medicinal composition containing puerarin in preparation of medicament with effect of preventing or treating senile dementia

A technology for senile dementia and puerarin, applied in the direction of drug combinations, medical preparations containing active ingredients, active ingredients of heterocyclic compounds, etc., can solve the problem of unclear application of Pueraria total flavonoids composition, prone to severe adverse reactions, Problems that do not meet the principles of medication, etc., to achieve the effect of improving motor function and therapeutic effect, improving cognitive ability and quality of life, and complementing the mechanism of drug action

Active Publication Date: 2014-01-22
INFINITUS (CHINA) CO LTD
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Patent application 200610046076.3 discloses a composition of kudzu root flavonoids and its application in the preparation and prevention of cardiovascular and cerebrovascular diseases, senile dementia, cerebral infarction, cerebral ischemia and other diseases caused by cerebral ischemia. Species containing the composition of Pueraria total flavonoids and Kudiezi total flavonoids and saponins, or the composition of Pueraria total flavonoids and Hippophae rhamnoides total flavonoids, the pharmaceutical composition contains a variety of unknown ingredients, which does not conform to the principles of modern m

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of puerarin or medicinal composition containing puerarin in preparation of medicament with effect of preventing or treating senile dementia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 Preparation of Puerarin Tablets

[0028] Puerarin 0.1g

[0029] Starch 25g

[0030] Dextrin 35g

[0031] Low-substituted hydroxypropyl cellulose 5g

[0032] 60% ethanol appropriate amount

[0033] Magnesium Stearate 1g

[0034] Preparation process: Weigh the prescribed amount of puerarin, starch, dextrin and low-substituted hydroxypropyl cellulose and mix evenly. Another appropriate amount of 60% (volume percentage, the same below) ethanol is added to the mixed powder, mixed evenly to make a soft material, granulated through a 16-mesh sieve, and dried below 60°C. After drying, use an 18-mesh sieve to carry out granulation, sieve out the fine powder in the dry granules, mix with the sieved magnesium stearate, and then mix with the dry granules evenly, and press into tablets to obtain the product. The content of puerarin in each preparation unit is 0.1 mg-200 mg, and the dosage for human use is 0.1 mg / kg·d~5 mg / kg·d.

Embodiment 2

[0035] Example 2 Preparation of Puerarin Tablets

[0036] Puerarin 25g

[0037] Microcrystalline Cellulose 180g

[0038] Hydroxypropyl Cellulose 15g

[0039] 8% (mass percentage content) starch slurry appropriate amount

[0040] Magnesium Stearate 1.5g

[0041] Preparation process: Weigh the prescribed amount of puerarin, microcrystalline cellulose and hydroxypropyl cellulose and mix evenly. Take another appropriate amount of 8% starch slurry solution, add it to the mixed powder, mix evenly to make soft material, pass through a 16-mesh sieve to granulate, and dry below 60°C. After drying, use an 18-mesh sieve to carry out granulation, sieve out the fine powder in the dry granules, mix with the sieved magnesium stearate, and then mix with the dry granules evenly, and press into tablets to obtain the product.

[0042] The content of puerarin in each preparation unit is 0.1mg~200mg, and the dosage for human use is 0.1mg / kg·d~5mg / kg·d.

Embodiment 3

[0043] Example 3 Preparation of Puerarin Tablets

[0044] Puerarin 25g

[0045] Triptolide 2.5g

[0046] Starch 25g

[0047] Dextrin 35g

[0048] Low-substituted hydroxypropyl cellulose 5g

[0049] 60% ethanol appropriate amount

[0050] Magnesium Stearate 1g

[0051] Preparation process: Weigh the prescription amount, puerarin, triptolide starch, dextrin and low-substituted hydroxypropyl cellulose and mix evenly. Take another appropriate amount of 60% ethanol, add it to the mixed powder, mix it evenly to make a soft material, granulate it through a 16-mesh sieve, and dry it below 60°C. After drying, use an 18-mesh sieve to carry out granulation, sieve out the fine powder in the dry granules, mix with the sieved magnesium stearate, and then mix with the dry granules evenly, and press into tablets to obtain the product. The content of puerarin in each preparation unit is 0.1 mg-200 mg, and the dosage for human use is 0.1 mg / kg·d~5 mg / kg·d.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of puerarin or a medicinal composition containing the puerarin in preparation of a medicament with an effect of preventing or treating senile dementia. The puerarin can be singly used as a medicament or can be used together with other senile dementia medicaments with different mechanisms of action when used for treating or preventing the senile dementia of people or mammals, wherein the puerarin not only can reduce side or toxic effects of medicaments but also can achieve an effective of collaborative treatment when used for treating the senile dementia together with a medicinal composition consisting of triptolide, galantamine and borneol. The puerarin can significantly inhibit the deposition of beta-amyloid, and has a definite curative effect and small side effects when used for preventing and treating the senile dementia, so that the puerarin has a wide medical application prospect.

Description

technical field [0001] The invention belongs to the technical field of puerarin, and in particular relates to the use of puerarin or a pharmaceutical composition containing puerarin in the preparation of medicaments for preventing or treating senile dementia. Background technique [0002] Alzheimer's disease, also known as Alzheimer's disease (Alzhimer's Disease, AD), is a degenerative disease of the central nervous system. Various schizophrenic symptoms and behavioral disturbances. With the development of the disease, patients will gradually lose their ability to take care of themselves, which will bring a heavy burden to the patient's personal family and society. Prevalence research shows that the number of Alzheimer's cases in the United States in 2000 was 4.5 million, and the percentage of Alzheimer's disease patients will increase by 2 times for every 5 years of age increase. The prevalence rate is 6%, compared with 30% in the 85-year-old population. At present, ther...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61K31/585A61P25/28A61K31/045A61K31/55
Inventor 蔡松赵宏伟王琦马忠华顾怀宇郭晓蕾
Owner INFINITUS (CHINA) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap